EF Hutton Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $17
Portfolio Pulse from Benzinga Newsdesk
EF Hutton has initiated coverage on Immunic (NASDAQ:IMUX) with a Buy rating and set a price target of $17, indicating a positive outlook for the company's stock.
September 16, 2024 | 12:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton has initiated coverage on Immunic with a Buy rating and a price target of $17, suggesting a positive short-term outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $17 by EF Hutton is a strong positive signal for investors. This suggests confidence in Immunic's potential, likely leading to increased investor interest and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100